PURPOSE: Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined. EXPERIMENTAL DESIGN: We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 BRCA mutation carriers and 806 noncarriers. Kruskal-Wallis tests were used to compare age of diagnosis and Gleason score, and logistic regression models were used to determine associations between carrier status, prostate cancer risk, and Gleason score. Hazard ratios (HR) for clinical end points were estimated using Cox proportional hazards models. RESULTS: BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score > or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer. BRCA1 mutations conferred no increased risk. After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers. CONCLUSIONS: BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course. These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer. Copyright 2010 AACR.
PURPOSE: Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined. EXPERIMENTAL DESIGN: We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 BRCA mutation carriers and 806 noncarriers. Kruskal-Wallis tests were used to compare age of diagnosis and Gleason score, and logistic regression models were used to determine associations between carrier status, prostate cancer risk, and Gleason score. Hazard ratios (HR) for clinical end points were estimated using Cox proportional hazards models. RESULTS:BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score > or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer. BRCA1 mutations conferred no increased risk. After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers. CONCLUSIONS:BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course. These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer. Copyright 2010 AACR.
Authors: R R Bahnson; G E Hanks; R P Huben; P Kantoff; J M Kozlowski; M Kuettel; P H Lange; C Logothetis; J M Pow-Sang; M Roach; H Sandler; P T Scardino; R J Taylor; D A Urban; P C Walsh; T G Wilson Journal: Oncology (Williston Park) Date: 2000-11 Impact factor: 2.990
Authors: S A Gayther; K A de Foy; P Harrington; P Pharoah; W D Dunsmuir; S M Edwards; C Gillett; A Ardern-Jones; D P Dearnaley; D F Easton; D Ford; R J Shearer; R S Kirby; A L Dowe; J Kelly; M R Stratton; B A Ponder; D Barnes; R A Eeles Journal: Cancer Res Date: 2000-08-15 Impact factor: 12.701
Authors: Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber Journal: J Natl Cancer Inst Date: 2002-09-18 Impact factor: 13.506
Authors: A Vazina; J Baniel; Y Yaacobi; A Shtriker; D Engelstein; I Leibovitz; M Zehavi; A A Sidi; Y Ramon; T Tischler; P M Livne; E Friedman Journal: Br J Cancer Date: 2000-08 Impact factor: 7.640
Authors: Arnaldo A Arbini; Margherita Greco; Jorge L Yao; Patricia Bourne; Ersilia Marra; Jer-Tsong Hsieh; Paul A di Sant'agnese; Loredana Moro Journal: Am J Pathol Date: 2011-05 Impact factor: 4.307
Authors: David J Gallagher; Angel M Cronin; Matthew I Milowsky; Michael J Morris; Jasmine Bhatia; Peter T Scardino; James A Eastham; Kenneth Offit; Mark E Robson Journal: BJU Int Date: 2011-07-14 Impact factor: 5.588
Authors: Richard Walker; Alyssa Louis; Alejandro Berlin; Sheri Horsburgh; Robert G Bristow; John Trachtenberg Journal: Can Urol Assoc J Date: 2014-11 Impact factor: 1.862
Authors: Marco Matejcic; Yesha Patel; Jenna Lilyquist; Chunling Hu; Kun Y Lee; Rohan D Gnanaolivu; Steven N Hart; Eric C Polley; Siddhartha Yadav; Nicholas J Boddicker; Raed Samara; Lucy Xia; Xin Sheng; Alexander Lubmawa; Vicky Kiddu; Benon Masaba; Dan Namuguzi; George Mutema; Kuteesa Job; Dabanja M Henry; Sue A Ingles; Lynne Wilkens; Loic Le Marchand; Stephen Watya; Fergus J Couch; David V Conti; Christopher A Haiman Journal: JCO Precis Oncol Date: 2020-01-31
Authors: Nassim Taherian; Nancy Hamel; Louis R Bégin; Tarek A Bismar; David E Goldgar; Bing-Jian Feng; William D Foulkes Journal: Nat Rev Urol Date: 2013-01-15 Impact factor: 14.432
Authors: P De Luca; C P Moiola; F Zalazar; K Gardner; E S Vazquez; A De Siervi Journal: Prostate Cancer Prostatic Dis Date: 2013-05-14 Impact factor: 5.554